AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00703833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0777
Description: Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
Study NCT00703833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (unspecified)
Description: matching placebo
Study NCT00465491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: picoplatin
Description: IV picoplatin 150mg/m2 q3wk
Study NCT00465491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: best supportive care
Description: best supportive care
Study NCT02150473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: adalimumab 40 mg every other week in combination with MTX for 24 weeks
Study NCT02150473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo the same amount as adalimumab
Study NCT03293498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu
Description: Vaccine
Study NCT00077610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa or beta
Description: intravenously 3 times weekly for 52 weeks, as prescribed
Study NCT00077610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO0503821 (1x/2 Weeks)
Description: 60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
Study NCT00077610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO0503821 (1x/4 Weeks)
Description: 120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
Study NCT04089020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support for walking to school
Description: 5 modules that address psychosocial skills, with ongoing text messaging.
Study NCT03494114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-EC2115
Description: Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
Study NCT04632706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
Study NCT04632706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to the Active IMP.
Study NCT00729131 — intervention group
Intervention type: DRUG
Intervention: Etanercept inhibition of ozone-induced airway hyper-responsiveness.
Description: Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
Study NCT04892316 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: The training dataset was used to train the model, which was validated and tested by the other two datasets.
Study NCT00897949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (MK0462)
Description: Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
Study NCT00897949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo to rizatriptan
Study NCT01553747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets twice daily
Study NCT01553747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets twice daily
Study NCT01197157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
Study NCT01197157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: • Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
Study NCT01810094 — intervention group
Intervention type: DEVICE
Intervention: Fracture Fixation
Description: Thoracolumbar Fracture Fixation
Study NCT03736759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
Study NCT03736759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
Study NCT01510652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiP Group
Description: Implantation of standard Left Ventricular (LV) lead
Study NCT01510652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quad Group
Description: Implantation of quadripolar Left ventricular (LV) lead Quartet
Study NCT03452124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I quit ordinary smoking (IQOS)
Description: I quit ordinary smoking (IQOS) assisted cessation program
Study NCT03452124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette
Description: Conventional cigarette smoking continuation
Study NCT01514994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioScore's Valvuloplasty Scoring Balloon
Description: All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
Study NCT00273741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
Study NCT00273741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo capsules
Study NCT04633655 — intervention group
Intervention type: OTHER
Intervention: outcome measures for CIPN testing
Description: questionnaires administration, physician based scales for CIPN data collection
Study NCT00110344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
Study NCT00110344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
Study NCT00897884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tablet, taken 3 times a day for 2-3 weeks
Study NCT03625076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular Lidocaine
Description: 20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
Study NCT03625076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedural Sedation with etomidate or propofol
Description: Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
Study NCT02145936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
Study NCT03861338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublocade
Description: The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
Study NCT02327767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resonating Arm Exerciser
Description: Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
Study NCT04028778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
Study NCT04028778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
Study NCT04028778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
Study NCT04028778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
Study NCT03005145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of adequate antibiotic treatment
Description: The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
Study NCT03005145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of adequate antibiotic treatment.
Description: The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
Study NCT00385710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Depakine
Study NCT00385710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05764421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor-cognitive intervention
Description: The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
Study NCT03809676 — intervention group
Intervention type: OTHER
Intervention: periodontal examination
Description: clinical measurements were recorded
Study NCT03398785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular chemical Ablation of Adrenal Gland
Description: Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
Study NCT01737320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short-course antibiotic treatment
Description: On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines.
Study NCT01737320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: accepted prolonged antibiotic treatment
Study NCT01188421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: up to 8/2 mg Sublingual (SL) per day
Study NCT01188421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: up to 0.8 mg per day (oral)
Study NCT01188421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol ER
Description: up to 600 mg per day
Study NCT00705289 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab used in line with current clinical practice and local guidelines.
Study NCT03144947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab IV
Description: Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase.
Study NCT03144947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC
Description: Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase.
Study NCT03293498 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD - Day 0
Description: Vaccine
Study NCT03144947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
Study NCT03144947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
Study NCT02662829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Study NCT02662829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Study NCT03055156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low rebound mattress toppers
Description: Patients will sleep on this mattress topper during their diagnostic sleep study.
Study NCT03293498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone HD - Day 21
Description: Vaccine
Study NCT03293498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline - Day 21
Description: Placebo
Study NCT01917097 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Study NCT01304342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
Study NCT01304342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intranasal fentanyl 200 micrograms 5 min before the ERCP
Study NCT01304342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline intravenously and intranasally
Study NCT03036813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voxelotor
Study NCT03036813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04333355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
Study NCT02928224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Orally, once daily.
Study NCT02928224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Orally, twice daily.
Study NCT02928224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Standard of care.
Study NCT02928224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Standard of care.
Study NCT02928224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Standard of care.
Study NCT02928224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: Standard of care.
Study NCT02928224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Standard of care.
Study NCT00813059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
Description: Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
Study NCT02961010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keeping Safe
Description: A whole school Preventative Education programme
Study NCT03009136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCRT
Description: composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
Study NCT03009136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
Study NCT01179334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
Study NCT01179334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study NCT01179334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
Study NCT01179334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
Study NCT02115139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
Study NCT04415528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Mindfulness Therapy
Description: EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention.